Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 15/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TACR3 | P29371 | 1/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5276651 | 1.00 | CYP1A2 (0.38) | CYP1A2TACR1KDM4ESMN1; SMN2BCHE | |
| SCHEMBL5317558 | 0.85 | CYP1A2 (0.39) | CYP1A2KDM4ESMN1; SMN2BCHEMEN1 | |
| SCHEMBL5238516 | 0.85 | CYP1A2 (0.41) | CYP1A2TACR1KDM4ESMN1; SMN2BCHE | |
| SCHEMBL5238518 | 0.85 | CYP1A2 (0.41) | CYP1A2TACR1KDM4ESMN1; SMN2BCHE | |
| SCHEMBL5235435 | 0.80 | CYP1A2 (0.35) | CYP1A2KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL5235444 | 0.80 | CYP1A2 (0.35) | CYP1A2KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL5239257 | 0.78 | CYP1A2 (0.41) | CYP1A2TACR1KDM4ESMN1; SMN2BCHE | |
| SCHEMBL5239266 | 0.78 | CYP1A2 (0.41) | CYP1A2TACR1KDM4ESMN1; SMN2BCHE | |
| SCHEMBL6102131 | 0.76 | ADRA1A (0.39) | TACR1SMN1; SMN2MEN1NPC1MAPT | |
| SCHEMBL6102141 | 0.76 | ADRA1A (0.39) | TACR1SMN1; SMN2MEN1NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1397364-B1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | LILLY CO ELI (US) | 2007-07-25 | — | — | EP | disclosed |
| US-7087626-B2 | Pyrrole derivatives as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2006-08-08 | — | — | US | disclosed |
| US-20040106604-A1 | Novel pyrrole derivatives as pharmaceutical agents | ELI LILLY AND COMPANY | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106604-A1 | Novel pyrrole derivatives as pharmaceutical agents | TGFBR1, SMAD3, TGFBR2 | CYP1A2 3968/4885TACR1 308/4885KDM4E 1699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.